Clinical Response Predictive Model for Omalizumab in Moderate-to-Severe Asthma Patients

Table 2

Change in clinical values between baseline and 16 weeks for omalizumab treatment.

	Baseline (n = 89)	After omalizumab treatment for 16 weeks (n = 89)	t/Z	value
FEV1	2.78 ± 0.85	2.99 ± 0.85	−4.29	≤0.001
FEV1%	86.65 ± 19.55	92.33 ± 17.77	−4.68	≤0.001
FEV1/FVC	74.39 ± 13.16	77.34 ± 12.21	−4.82	≤0.001
FVC	3.80 ± 0.98	3.89 ± 1.00	2.23	0.029
PEF	7.58 ± 2.49	7.85 ± 2.35	2.19	0.032
PEF%pre	95.68 ± 27.16	99.32 ± 24.61	2.25	0.027
MEF 75%pre	78.15 ± 35.95	83.44 ± 34.78	2.92	0.005
MEF 50%pre	62.84 ± 37.55	65.64 ± 36.26	1.89	0.062
MEF 25%pre	51.61 ± 37.49	53.78 ± 36.23	1.25	0.215
MMEF 75/25%pre	57.73 ± 35.43	60.72 ± 34.29	2.18	0.033
FeNO	34 (21–62.75)	22 (17–37)	−5.86	≤0.001
ACT	18 (16.5–19)	23 (21–23)	−7.98	≤0.001
ACQ	1.78 ± 0.58	0.94 ± 0.48	−17.72	≤0.001
MiniAQLQ	70.58 ± 10.42	86.03 ± 7.34	13.94	≤0.001
EOS	0.21 (0.10–0.40)	0.15 (0.09–0.27)	−4.11	≤0.001
IgE	271.85 (131.00–426.80)	743.10 (405.85–1104.00)	−7.57	≤0.001

FEV1: forced expiratory volume in one second; FEV1%: FEV1 percentage of predicted; FVC: forced vital capacity; PEF: peak expiratory flow; PEF%pre: PEF percentage of predicted; MEF75%pre: maximal expiratory flow after 75% of FVC (MEF75) has not been exhaled percentage of predicted; MEF50%pre: maximal expiratory flow after 50% of FVC has not been exhaled (MEF50) percentage of predicted; MEF25%pre: maximal expiratory flow after 25% of FVC has not been exhaled (MEF25) percentage of predicted; MMEF 75/25%pre: maximal mid-expiratory flow (MMEF 75/25) percentages of predicted; FeNO: fractional exhaled nitric oxide; ACT: asthma control test; MiniAQLQ: the 15-item Mini Asthma Quality of Life Questionnaire. The bold values indicate that the differences observed are statistically significant ().